Regular Article
In Vitro Metabolism of CP-122,721 ((2S,3S)-2-Phenyl-3-[(5-Trifluoromethoxy-2-Methoxy)Benzylamino]Piperidine), a Non-Peptide Antagonist of the Substance P Receptor

https://doi.org/10.2133/dmpk.22.336Get rights and content

Summary:

The metabolism of CP-122,721, a neurokinin-1 antagonist, has been examined in vitro using hepatic microsomes from human and animal species, and recombinant heterologously expressed P450 enzymes. Metabolism occurs primarily via O-demethylation and N-dealkylation reactions. In human liver microsomes, O-demethylation was shown to be catalyzed by CYP2D6 with a low KM value. N-dealkyation was shown to be catalyzed primarily by CYP3A4. When scaled to in vivo, in vitro intrinsic clearance data yielded a reasonable correlation across species. CP-122,721 was shown to be metabolized by parallel pathways to 5-trifluoromethoxysalicylic acid, which had been observed as a major circulating metabolite in humans after oral administration of CP-122,721. The involvement of CYP1A2, CYP3A4, and MAO-B was demonstrated in the pathways leading to 5-trifluoromethoxysalicylic acid. The O-desmethyl metabolite of CP-122,721 was shown to undergo a P450 catalyzed O-detrifluoromethylation reaction yielding a p-hydroquinone metabolite. The reaction was shown to be catalyzed by CYP3A4. Incubation under 18O2 yielded the hydroquinone containing O-18, consistent with this reaction occurring via an ispo substitution mechanism. Combined, these findings provide a comprehensive understanding of the metabolism of this new agent.

References (33)

  • Z. Gesztesi et al.

    Substance P (neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures

    Anesthesiology

    (2000)
  • T. Omura et al.

    The carbon monoxide binding pigment of liver microsomes

    J. Biol. Chem.

    (1964)
  • K.S. Pang et al.

    Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

    J. Pharmacokinet. Biopharm.

    (1977)
  • T.D. Bjornsson et al.

    The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

    Drug Metab. Dispos.

    (2003)
  • K. Brosen

    Antiarrythmics

  • S.A. Wrighton et al.

    Inhibition of CYP3A catalyzed 1′-hydroxymidazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine

    Pharm. Res.

    (1994)
  • Cited by (12)

    • An Introduction to Metabolic Reaction-Phenotyping

      2022, DRUG METABOLISM HANDBOOK: CONCEPTS AND APPLICATIONS IN CANCER RESEARCH
    View all citing articles on Scopus
    View full text